BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35962148)

  • 1. A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
    Bright EE; Genung SR; Stanton AL; Arch JJ
    Breast Cancer Res Treat; 2022 Oct; 195(3):393-399. PubMed ID: 35962148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.
    Arch JJ; Crespi CM; Levin ME; Genung SR; Nealis M; Mitchell JL; Bright EE; Albright K; Magidson JF; Stanton AL
    Ann Behav Med; 2022 Aug; 56(8):856-871. PubMed ID: 35323853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
    Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
    J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
    Uslu Y; Kocatepe V; Sezgin DS; Uras C
    Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
    Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
    Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.
    AlOmeir O; Patel N; Donyai P
    Support Care Cancer; 2020 Nov; 28(11):5075-5084. PubMed ID: 32601852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
    Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
    J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis.
    Finitsis DJ; Vose BA; Mahalak JG; Salner AL
    Psychooncology; 2019 Feb; 28(2):255-263. PubMed ID: 30511789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
    Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
    Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
    Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
    Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
    Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
    Lundgren C; Lindman H; Rolander B; Ekholm M
    Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
    Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
    Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
    Jacobs JM; Walsh EA; Rapoport CS; Antoni MH; Park ER; Post K; Comander A; Peppercorn J; Safren SA; Temel JS; Greer JA
    J Clin Psychol Med Settings; 2021 Sep; 28(3):603-618. PubMed ID: 33219901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.